Astonea Labs Ltd (ASTONEALAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Astonea Labs Ltd on NSE and BSE, with an AI summary of each filing.
Astonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve unaudited Standalone and Consolidated ....
Intimation · 14 Nov 2026, 5:30 am
Astonea Labs to Consider Half-Year Results on 14th Nov'26 Astonea Labs Limited has scheduled a Board of Directors meeting on 14th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the half-year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for dealing in company equity shares has been closed from 1st Oct'26 and will remain shut until 48 hours post the announcement of financial results on 14th Nov'26.
Please find enclosed herewith an Intimation regarding change in the Corporate Identification Number (CIN) of the Company consequent upon alteration of the Object Clause of the Memorandum ....
Others (Uncategorized) · 09 Oct 2026, 8:24 pm
Astonea Labs Updates Corporate Identification Number Following Object Clause Alteration Astonea Labs Limited has changed its Corporate Identification Number (CIN) to L21001CH2017PLC041482 from L24304CH2017PLC041482, effective 9th Oct'26. The revision follows shareholder approval at the AGM on 21st Aug'26 to alter the company's Memorandum of Association Object Clause, triggering a reclassification of its business activity under the applicable National Industrial Classification (NIC) Code. The Ministry of Corporate Affairs registered the alteration under Section 13(1) of the Companies Act, 2013, confirming the regulatory formalisation of the updated corporate identification.
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Incorporation of Proposed Subsidiary- Longevity Science Private Limited
Others (Uncategorized) · 08 Oct 2026, 10:41 pm
Astonea Labs Incorporates 51%-Owned Subsidiary Longevity Science Astonea Labs Limited announced the incorporation of a new subsidiary, Longevity Science Private Limited, on 8th Oct'26. The company will acquire a 51% controlling stake by subscribing to 51,000 initial equity shares at ₹10 each, totaling a cash consideration of ₹5,10,000 on an arm's-length basis. The newly incorporated entity will operate in the pharmaceuticals, healthcare, nutraceuticals, and allied products sector in India. No specific regulatory approvals are required beyond standard statutory filings.
Please find enclosed herewith re-submission of financial results for the half year and year ended 31.03.2025.
Financial Result · 22 Sept 2026, 7:36 pm
Astonea Labs Posts Strong FY25 Financial Results Following Clarification Submission to BSE Astonea Labs clarified and submitted its standalone financial results for the half-year and full-year ended 31st Mar'25. For FY25, revenue from operations rose 21.6% YoY to ₹9,751.83 lakh versus ₹8,019.09 lakh in FY24. Profit after tax increased 31.4% YoY to ₹535.05 lakh from ₹407.01 lakh, while annual EPS improved to ₹6.94 from ₹5.36. For H2 FY25, revenue reached ₹5,024.80 lakh and net profit stood at ₹321.63 lakh. Net cash flows from operating activities strengthened to ₹924.95 lakh for FY25.
Please find enclosed herewith resubmission of financial results for the financial year ended 31.03.2025, as the same was submitted in XBRL Version and as a part of outcome of the Board ....
Financial Result · 19 Sept 2026, 5:11 pm
Astonea Labs Resubmits FY25 Financial Results Rectifying Regulatory Discrepancies Astonea Labs Limited resubmitted its standalone audited financial results and unmodified auditor's report for the fiscal year ended 31st Mar'25 to rectify BSE filing discrepancies. The company clarified that results previously submitted in XBRL mode on 11th Jul'25 omitted the separate PDF format and Regulation 33(3) declaration under corporate announcements. For FY25, revenue from operations grew 21.61% YoY to ₹9,751.83 lakhs compared to ₹8,019.09 lakhs in FY24. Net profit increased 31.46% YoY to ₹535.05 lakhs, with basic and diluted EPS rising to ₹6.94 from ₹5.36.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashish Gulati
Acquisition/ Disposal of Shares · 18 Sept 2026, 4:10 pm
Promoter Ashish Gulati Increases Stake in Astonea Labs via Open Market Acquisition Promoter Ashish Gulati acquired 14,000 equity shares (0.13% stake) of Astonea Labs Ltd via open-market purchases between 15th Sep'26 and 16th Sep'26. Following this transaction, his total holding alongside Persons Acting in Concert (PACs) increased from 74,42,970 shares (70.81%) to 74,56,970 shares (70.94%) of the total voting capital. The company's total equity share capital remains unchanged at 1,05,11,000 shares. The disclosure was submitted voluntarily under SEBI (SAST) Regulation 29(1) for transparency and corporate governance.
Please find enclosed herewith disclosure under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulation, 2015 as received from Mr. Ashish Gulati, Promoter of the Company.
Others (Uncategorized) · 17 Sept 2026, 9:55 pm
Promoter Ashish Gulati Acquires 14,000 Equity Shares in Astonea Labs Astonea Labs Limited disclosed that promoter Ashish Gulati acquired 14,000 equity shares via open market transactions on the BSE on 15th Sep'26 and 16th Sep'26. Following the acquisitions, his equity stake in the company increased from 74,42,970 shares (70.81%) to 74,56,970 shares (70.94%).
Please find enclosed herewith disclosure as per Regulation 29(1) of SEBI (Substantial Acquisition of shares & Takeovers) Regulation, 2011 as received from Mr. Ashish Gulati, Promoter of the Company.
Others (Uncategorized) · 17 Sept 2026, 9:36 pm
Astonea Labs Promoter Acquires 14,000 Equity Shares via Open Market Promoter Ashish Gulati acquired 14,000 equity shares (0.13% stake) of Astonea Labs Limited through open market transactions conducted on 15th Sep'26 and 16th Sep'26. Following this acquisition, the promoter and PAC holding increased from 74,42,970 shares (70.81%) to 74,56,970 shares (70.94%) out of the company's total equity base of 1,05,11,000 shares. The disclosure was submitted voluntarily under Regulation 29(1) of SEBI SAST Regulations.
Intimation under Regulation 30-Appointment of Internal Auditor
Change in Auditor · 09 Sept 2026, 11:09 pm
Astonea Labs Appoints Internal Auditor for FY27 The Board of Directors of Astonea Labs Limited, on the recommendation of the Audit Committee, approved the appointment of Mr. Chander Shekhar of M/s. Chander Shekhar & Associates (FRN: 020828N) as the Internal Auditor of the company on 9th Sep'26. The appointment is effective for the financial year FY27 pursuant to Section 138 of the Companies Act, 2013. Mr. Shekhar is an ICAI-qualified Chartered Accountant with extensive experience across internal audit, accounting, taxation, and financial reporting.
Outcome of the Board Meeting held on 9th September, 2026.
Others (Uncategorized) · 09 Sept 2026, 10:50 pm
Astonea Labs Approves Subsidiary Incorporation, US Investment, and Agreement Terminations Astonea Labs' Board approved the incorporation of Longevity Science Private Limited as a subsidiary with at least a 51% stake. It also cleared an initial Overseas Direct Investment of up to USD 10,000 in its wholly-owned US subsidiary, Astonea LLC (Wyoming). Additionally, the Board confirmed the immediate termination of the Material Supply & Manufacturing Agreement and Distribution, Marketing & Brand License Agreement with Astonea One Private Limited. The clean Cost Audit Report for FY25-26 was recorded, and Chander Shekhar was appointed Internal Auditor for FY26-27.
Approval of Alteration in Object Clause of the Memorandum of Association ("MOA") of the Company
Others (Uncategorized) · 22 Aug 2026, 12:54 am
Astonea Labs Alters MOA to Expand Business Scope Astonea Labs received shareholder approval via a special resolution on 21st Aug'26 to alter its Memorandum of Association's object clause. This strategic change expands the company's scope to include manufacturing, marketing, and sale of pharmaceutical, nutraceutical, healthcare, and ayurvedic products. The expansion covers multiple commercial channels, including retail, wholesale, institutional sales, franchise arrangements, and e-commerce platforms. This move aligns the company's legal framework with its existing and proposed business activities, facilitating broader market reach and operational flexibility.
Re-appointment of Ms. Pooja Singh as Director of the Company
Others (Uncategorized) · 22 Aug 2026, 12:40 am
Astonea Labs Re-appoints Ms. Pooja Singh as Director Astonea Labs announced the re-appointment of Ms. Pooja Singh (DIN: 10547745) as a Director, effective 21st Aug'26, following approval at its 9th AGM. The re-appointment is for a term liable to retirement by rotation. Ms. Singh, who heads the Drug Regulatory Affairs department, brings over eight years of pharmaceutical industry experience, specializing in Quality Assurance and Regulatory Compliance. She holds a Bachelor of Pharmacy degree. Ms. Singh has no relation to other directors/KMP and holds no shares in the company.
Scrutinizer''s Reports and Voting Results of the 9th Annual General Meeting ("AGM") of the Company held on 21st August, 2026
Annual General Meeting · 22 Aug 2026, 12:16 am
Proceedings of 9th Annual General Meeting ("AGM") of the Company for the financial year 2025-26 held on 21st August, 2026
Annual General Meeting · 21 Aug 2026, 10:01 pm
Annual Report of the Company for the Financial year 2025-26.
Others (Uncategorized) · 25 Jul 2026, 2:58 am
Please find enclosed herewith an attached Notice of 9th Annual General Meeting ("AGM") of the Company for the Financial Year 2025-26 scheduled to be held on Friday, 21st August, 2026.
Annual General Meeting · 25 Jul 2026, 1:15 am
Intimation under Regulation 30- Revision in Re-appointment of Tax Auditor under Income Tax Act, 2025
Change in Auditor · 25 Jul 2026, 12:42 am
Astonea Labs Confirms Tax Auditor Re-appointment Under New Income-tax Act Astonea Labs' Board approved an amendment on 24th Jul'26 to its 30th May'26 resolution concerning its Tax Auditor. This administrative change updates statutory references from the Income-tax Act, 1961 to the newly applicable Income-tax Act, 2025. The Board re-confirmed the re-appointment of M/s. Avnish Sharma & Associates as Tax Auditor for FY ending 31st Mar'27. The amendment is consequential, with no change to the auditor's remuneration, terms, or conditions, ensuring continuity in corporate governance and compliance.
Audited Consolidated Financial Results for the Half year and year ended 31.03.2026
Financial Result · 24 Jul 2026, 11:18 pm
Astonea Labs Board Approves FY26 Results and Key Strategic Initiatives On 24 Jul'26, Astonea Labs' board approved the audited consolidated financial results for the year ended 31 Mar'26. FY26 consolidated revenue from operations was ₹14,758.44 lakh, with a net profit of ₹451.54 lakh and a basic EPS of ₹4.49. The board also approved alterations to the MOA to expand business activities, the incorporation of new subsidiaries, and the re-appointment of Ms. Pooja Singh as Director. Additionally, the 9th AGM is scheduled for 21 Aug'26 to seek shareholder approvals.
Outcome of the Board Meeting held on 24th July, 2026
Outcome · 24 Jul 2026, 11:06 pm
Astonea Labs Approves FY26 Results, Expansion Plans, and New Subsidiaries On 24 Jul'26, Astonea Labs' board approved audited consolidated financials for FY ended 31 Mar'26, reporting a Profit After Tax of ₹451.54 lakhs. Key approvals included the alteration of the MOA to expand into new pharmaceutical and healthcare product lines, and the incorporation of new subsidiary companies in India to drive growth. The board also approved the annual report, a proposal for the re-appointment of Director Ms. Pooja Singh, and the notice for the 9th AGM scheduled for 21 Aug'26.
Astonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2026 ,inter alia, to consider and approve Audited Consolidated Financial ....
Intimation · 24 Jul 2026, 5:30 am
Astonea Labs Board to Approve FY26 Results on 24th July Astonea Labs has scheduled a board meeting on 24th Jul'26 to consider and approve its audited consolidated financial results for the year ended 31st Mar'26. Other key agenda items include approving the annual report, altering the Memorandum of Association (MOA), and considering the incorporation of and investment in a new subsidiary. The trading window for insiders has been closed since 1st Apr'26 and will reopen 48 hours after the results are declared. Standalone results were announced on 30th May'26.
Intimation under Regulation 30 of SEBI(LODR)Regulations, 2015 - Execution and Registration of Sale Deed for Sale of Immovable Properties located in Gurugram, Haryana.
Others (Uncategorized) · 17 Jul 2026, 11:41 pm
Astonea Labs Sells Gurugram Commercial Properties for ~Rs 2.99 Crore Astonea Labs Limited has sold two commercial units in Gurugram for a total consideration of approximately Rs 2.99 crore. On 17th Jul'26, the company executed the sale deed for units FF-508 and FF-509, each 1,361 sq. ft., in the JMD Megapolis IT Park. The sale consideration was Rs 1,49,71,000 for each unit. The company states the rationale is to monetize assets, optimize its portfolio, and strengthen its financial position. The transaction is not with a related party and is not expected to materially impact operations.
Intimation under Regulation 30 regarding successful completion of Regulatory Inspection of Manufacturing Facility by Supreme Board of Drugs and Medical Appliances (SBDMA), Ministry of Health ....
Others (Uncategorized) · 15 Jul 2026, 12:28 am
Astonea Labs Completes Successful Yemen Regulatory Inspection Astonea Labs announced on 14th Jul'26 the successful completion of an inspection of its manufacturing facility in Panchkula, Haryana. The inspection was conducted by Yemen's Supreme Board of Drugs and Medical Appliances (SBDMA). The company has received the requisite certificate from the regulatory authority, confirming the successful audit. This development is a positive regulatory clearance, potentially facilitating market access or continued business in Yemen.
Please find enclosed the Revised Financial Results along with the additional documents sought by BSE through its email dated 19th June 2026
Financial Result · 20 Jun 2026, 10:11 pm
Astonea Labs Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 8,129 (Negative to Positive YoY | +22.6% QoQ) ■ EBITDA: 799 (Loss to Profit YoY | +48.8% QoQ) ■ EBITDA Margin (%): 9.8 (-19018 bps YoY | +173 bps QoQ) ■ PAT: 310 (Loss to Profit YoY | +118.5% QoQ) ■ EPS (INR): 3.08 (Loss to Profit YoY | +118.4% QoQ)
Submission of Half-Yearly Disclosure on Related Party Transactions for the period ended 31.03.2026
Others (Uncategorized) · 31 May 2026, 3:18 am
Astonea Labs Discloses Related Party Transactions for H2FY26 Astonea Labs Limited disclosed related party transactions for the half-year ended 31 Mar'26. Total transactions during the period amounted to ₹3,204.06 lakhs. Key transactions include sales of goods or services to associate Astonea One Private Limited totaling ₹2,627.74 lakhs, and to Ascot Biolabs Private Limited for ₹138.04 lakhs. Significant remuneration was paid to Managing Director Ashish Gulati (₹60.33 lakhs). Loans were also provided to Harsh Gulati and Usha Gulati, both relatives of a director, with outstanding balances of ₹190.35 lakhs and ₹160.35 lakhs respectively.
Statement of Deviation & Variation for the half year ended 31.03.2026
Others (Uncategorized) · 31 May 2026, 3:07 am
Astonea Labs Reports IPO Fund Reallocation for Strategic Investment Astonea Labs has reallocated IPO proceeds following approvals from its board on 27th Feb'26 and shareholders on 27th Mar'26. Of the total Rs. 37.67cr raised, the company will reallocate Rs. 6.25cr towards acquiring an equity stake in Damaira Pharmaceuticals Private Limited as a strategic investment. This reallocation reduces funds originally earmarked for South American registration and machinery purchases. As of 31st Mar'26, Rs. 35.91cr has been utilized, with Rs. 1.75cr remaining unutilised from the initial issue.